In this review:
ADVANCE study: renal outcomes
Insulin plus GLP-1 receptor agonists
Liraglutide reduces insulin dose: no loss of glycaemic control
Liraglutide: promising weight loss data
Long-term, injection-free exenatide
Dapagliflozin + metformin in type 2 diabetes
Please login below to download this issue (PDF)